Niacin action in the atherogenic mixed dyslipidemia of metabolic syndrome: Insights from metabolic biomarker profiling and network analysis

Digby, 2012, Niacin in cardiovascular disease: recent preclinical and clinical developments, Arterioscler Thromb Vasc Biol, 32, 582, 10.1161/ATVBAHA.111.236315 Lavigne, 2013, The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression, J Am Coll Cardiol, 61, 440, 10.1016/j.jacc.2012.10.030 Chapman, 2011, Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management, Eur Heart J, 32, 1345, 10.1093/eurheartj/ehr112 Superko, 2017, Niacin and heart disease prevention: Engraving its tombstone is a mistake, J Clin Lipidol, 11, 1309, 10.1016/j.jacl.2017.08.005 Lamon-Fava, 2008, Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins, Arterioscler Thromb Vasc Biol, 28, 1672, 10.1161/ATVBAHA.108.164541 Blond, 2014, Nicotinic acid effects on insulin sensitivity and hepatic lipid metabolism: an in vivo to in vitro study, Horm Metab Res, 46, 390, 10.1055/s-0034-1372600 Wang, 2001, Effect of nicotinic acid administration on hepatic very low density lipoprotein-triglyceride production, Am J Physiol Endocrinol Metab, 280, E540, 10.1152/ajpendo.2001.280.3.E540 Le Bloc'h, 2010, Nicotinic acid decreases apolipoprotein B100-containing lipoprotein levels by reducing hepatic very low density lipoprotein secretion through a possible diacylglycerol acyltransferase 2 inhibition in obese dogs, J Pharmacol Exp Ther, 334, 583, 10.1124/jpet.110.167478 Fabbrini, 2010, Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease, J Clin Endocrinol Metab, 95, 2727, 10.1210/jc.2009-2622 Pang, 2014, Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus, Arterioscler Thromb Vasc Biol, 34, 427, 10.1161/ATVBAHA.113.302019 Ooi, 2015, Effects of extended-release niacin on the postprandial metabolism of Lp(a) and ApoB-100-containing lipoproteins in statin-treated men with type 2 diabetes mellitus, Arterioscler Thromb Vasc Biol, 35, 2686, 10.1161/ATVBAHA.115.306136 Zhang, 2012, Niacin increases HDL biogenesis by enhancing DR4-dependent transcription of ABCA1 and lipidation of apolipoprotein A-I in HepG2 cells, J Lipid Res, 53, 941, 10.1194/jlr.M020917 Ganji, 2004, Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells, J Lipid Res, 45, 1835, 10.1194/jlr.M300403-JLR200 Hu, 2012, Liver fat reduction with niacin is influenced by DGAT-2 polymorphisms in hypertriglyceridemic patients, J Lipid Res, 53, 802, 10.1194/jlr.P023614 Lauring, 2012, Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression, Sci Transl Med, 4, 148ra115, 10.1126/scitranslmed.3003877 Robins, 2011, Insulin resistance and the relationship of a dyslipidemia to coronary heart disease: the Framingham Heart Study, Arterioscler Thromb Vasc Biol, 31, 1208, 10.1161/ATVBAHA.110.219055 Lee, 2009, Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study, J Am Coll Cardiol, 54, 1787, 10.1016/j.jacc.2009.06.036 Investigators, 2011, Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy, N Engl J Med, 365, 2255, 10.1056/NEJMoa1107579 Group, 2014, Effects of extended-release niacin with laropiprant in high-risk patients, N Engl J Med, 371, 203, 10.1056/NEJMoa1300955 Vega, 2005, Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia, Am J Cardiol, 95, 1309, 10.1016/j.amjcard.2005.01.073 Digby, 2010, Anti-inflammatory effects of nicotinic acid in adipocytes demonstrated by suppression of fractalkine, RANTES, and MCP-1 and upregulation of adiponectin, Atherosclerosis, 209, 89, 10.1016/j.atherosclerosis.2009.08.045 Lukasova, 2011, Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells, J Clin Invest, 121, 1163, 10.1172/JCI41651 Digby, 2012, Anti-inflammatory effects of nicotinic acid in human monocytes are mediated by GPR109A dependent mechanisms, Arterioscler Thromb Vasc Biol, 32, 669, 10.1161/ATVBAHA.111.241836 Wu, 2012, Niacin inhibits vascular inflammation via the induction of heme oxygenase-1, Circulation, 125, 150, 10.1161/CIRCULATIONAHA.111.053108 Kang, 2011, Effects of nicotinic acid on gene expression: potential mechanisms and implications for wanted and unwanted effects of the lipid-lowering drug, J Clin Endocrinol Metab, 96, 3048, 10.1210/jc.2011-1104 Plaisance, 2009, Niacin stimulates adiponectin secretion through the GPR109A receptor, Am J Physiol Endocrinol Metab, 296, E549, 10.1152/ajpendo.91004.2008 Rosenson, 2003, Antiatherothrombotic effects of nicotinic acid, Atherosclerosis, 171, 87, 10.1016/j.atherosclerosis.2003.07.003 Sorrentino, 2010, Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy, Circulation, 121, 110, 10.1161/CIRCULATIONAHA.108.836346 Zandi-Nejad, 2013, The role of HCA2 (GPR109A) in regulating macrophage function, FASEB J, 27, 4366, 10.1096/fj.12-223933 Feingold, 2014, Inflammation stimulates niacin receptor (GPR109A/HCA2) expression in adipose tissue and macrophages, J Lipid Res, 55, 2501, 10.1194/jlr.M050955 Alberti, 2005, The metabolic syndrome–a new worldwide Definition, Lancet, 366, 1059, 10.1016/S0140-6736(05)67402-8 Orsoni, 2011, LDL-apheresis depletes apoE-HDL and pre-beta1-HDL in familial hypercholesterolemia: relevance to atheroprotection, J Lipid Res, 52, 2304, 10.1194/jlr.P016816 Sheskin, 2003 Storey, 2003, The positive false discovery rate: a Bayesian interpretation and the q-value, Ann Stat, 31, 2013, 10.1214/aos/1074290335 Ideker, 2012, Differential network biology, Mol Syst Biol, 8, 565, 10.1038/msb.2011.99 Makki, 2013, The epidermal growth factor receptor and its ligands in cardiovascular disease, Int J Mol Sci, 14, 20597, 10.3390/ijms141020597 Ference, 2017, Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel, Eur Heart J, 38, 2459, 10.1093/eurheartj/ehx144 Warnholtz, 2009, Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF study, Atherosclerosis, 204, 216, 10.1016/j.atherosclerosis.2008.08.003 Pechlaner, 2017, Very-low-density lipoprotein-associated apolipoproteins predict cardiovascular events and are lowered by inhibition of APOC-III, J Am Coll Cardiol, 69, 789, 10.1016/j.jacc.2016.11.065 Karimi Galougahi, 2015, Redox biomarkers in cardiovascular medicine, Eur Heart J, 36, 1576, 10.1093/eurheartj/ehv126 Emdin, 2005, Gamma-glutamyltransferase, atherosclerosis, and cardiovascular disease: triggering oxidative stress within the plaque, Circulation, 112, 2078, 10.1161/CIRCULATIONAHA.105.571919 Chao, 2000, Effects of methionine-induced hyperhomocysteinemia on endothelium-dependent vasodilation and oxidative status in healthy adults, Circulation, 101, 485, 10.1161/01.CIR.101.5.485 Ginsberg, 2000, Insulin resistance and cardiovascular disease, J Clin Invest, 106, 453, 10.1172/JCI10762 Rotter, 2003, Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects, J Biol Chem, 278, 45777, 10.1074/jbc.M301977200 Matsumoto, 2017, Cystatin C-Adiponectin Complex in plasma associates with coronary plaque instability, J Atheroscler Thromb, 24, 970, 10.5551/jat.39545 Ruan, 2016, Adiponectin signalling and function in insulin target tissues, J Mol Cell Biol, 8, 101, 10.1093/jmcb/mjw014 Weisberg, 2003, Obesity is associated with macrophage accumulation in adipose tissue, J Clin Invest, 112, 1796, 10.1172/JCI200319246 Akira, 1996, Role of interleukin-6 in macrophage function, Curr Opin Hematol, 3, 87, 10.1097/00062752-199603010-00013 Taskinen, 2016, Why is apolipoprotein CIII emerging as a novel therapeutic target to reduce the burden of cardiovascular disease?, Curr Atheroscler Rep, 18, 59, 10.1007/s11883-016-0614-1